The IBN SINA Pharmaceutical Industry (DHA:IBNSINA) Intangible Assets: BDT0.00 Mil (As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DHA:IBNSINA The IBN SINA Pharmaceutical Industry PLC DHA:IBNSINA
20 GF Score
Price BDT316.90
View Full Analysis

What is The IBN SINA Pharmaceutical Industry Intangible Assets?

The IBN SINA Pharmaceutical Industry DHA:IBNSINA -0.22% 20 Intangible Assets is BDT0.00 Mil as of . 20. GuruFocus rates DHA:IBNSINA with a GF Score™ of 20/100.

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. The IBN SINA Pharmaceutical Industry's intangible assets for the quarter that ended in . 20 was BDT0.00 Mil.


The IBN SINA Pharmaceutical Industry  (DHA:IBNSINA) Intangible Assets Explanation

If a company (company A) received a patent through their own work, though it has value, it does not show up on its balance sheet as an intangible asset. However, if company A sells this patent to company B, it will show up on company B's balance sheet as an intangible asset.

The same applies to brand names, trade secrets etc. For instance, Coca-Cola's brand is extremely valuable, but the brand does not appear on its balance sheet, because the brand was never acquired.

Some intangibles are amortized. Amortization is the depreciation of intangible assets.

Many intangibles are not amortized. They may still be written down when the company decides the asset is impaired.

Whenever you see an increase in goodwill over a number of years, you can assume it's because the company is out buying other businesses above book value. GOOD if buying businesses with durable competitive advantage.

If goodwill stays the same, the company when acquiring other companies is either paying less than book value or not acquiring. Businesses with moats never sell for less than book value.

Intangibles acquired are on balance sheet at fair value.

Internally developed brand names (Coke, Wrigleys, Band-Aid) however are not reflected on the balance sheet.

One of the reasons competitive advantage power can remain hidden for so long.


Be Aware

Companies may change the way intangible assets are amortized, and this will affect their reported earnings.


The IBN SINA Pharmaceutical Industry Intangible Assets Related Terms


The IBN SINA Pharmaceutical Industry Intangible Assets Historical Data

* Premium members only.

The historical data trend for The IBN SINA Pharmaceutical Industry's Intangible Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The IBN SINA Pharmaceutical Industry Intangible Assets Chart

The IBN SINA Pharmaceutical Industry Annual Data
Trend
Intangible Assets

The IBN SINA Pharmaceutical Industry Semi-Annual Data
Intangible Assets
DHA:IBNSINA
20GF Score
The IBN SINA Pharmaceutical Industry PLC DHA:IBNSINA
Intangible Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

The IBN SINA Pharmaceutical Industry Intangible Assets Calculation

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Examples of intangible assets include trade secrets, copyrights, patents, trademarks. If a company acquires assets at the prices above the book value, it may carry goodwill on its balance sheet. Goodwill reflects the difference between the price the company paid and the book value of the assets.

Frequently Asked Questions Learn more about Intangible Assets →
What does a Intangible Assets of BDT0.00 Mil mean?
The IBN SINA Pharmaceutical Industry (DHA:IBNSINA) has a Intangible Assets of BDT0.00 Mil as of . 20. Intangible assets include patents, goodwill and trade secrets. View historical data on The IBN SINA Pharmaceutical Industry and its competitors.
Is The IBN SINA Pharmaceutical Industry's Intangible Assets too high?
The IBN SINA Pharmaceutical Industry's current Intangible Assets is BDT0.00 Mil. Overall, The IBN SINA Pharmaceutical Industry has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does The IBN SINA Pharmaceutical Industry's Intangible Assets compare to IMNPQ?
The IBN SINA Pharmaceutical Industry's Intangible Assets of BDT0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intangible Assets for a Drug Manufacturers company?
A good Intangible Assets depends on the Drug Manufacturers industry context. However, Intangible Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intangible Assets mean?
A high Intangible Assets can signal that a stock is expensive relative to its fundamentals. Intangible assets include patents, goodwill and trade secrets. View historical data on The IBN SINA Pharmaceutical Industry and its competitors. The IBN SINA Pharmaceutical Industry's current Intangible Assets is BDT0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The IBN SINA Pharmaceutical Industry stock overvalued right now?
The IBN SINA Pharmaceutical Industry (DHA:IBNSINA) has a current Intangible Assets of BDT0.00 Mil. The current Intangible Assets is BDT0.00 Mil. The IBN SINA Pharmaceutical Industry's overall GF Score™ is 20/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intangible Assets calculated?
Intangible Assets is calculated from a company's financial statements. For The IBN SINA Pharmaceutical Industry (DHA:IBNSINA), the current Intangible Assets is BDT0.00 Mil as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

The IBN SINA Pharmaceutical Industry Business Description

Address Mirpur Road, Tanin Center, 3 Asad Gate, Mohammadpur, Dhaka, BGD, 1207
The IBN SINA Pharmaceutical Industry PLC is engaged in the production and marketing of pharmaceutical drugs and natural medicines in both the local and international market.
20GF Score

Get the complete analysis for DHA:IBNSINA

Intangible Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT316.90
Price